Buscar

Estamos realizando la búsqueda. Por favor, espere...

Anti-TNF-a therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study

Abstract: Objective: Psoriasis is a chronic inflammatory disease associated with increased risk of cardiovascular death. Several studies have shown a beneficial effect of anti-TNF-a therapy on the mechanisms associated with accelerated atherogenesis in patients with inflammatory arthritis, including an improvement of insulin sensitivity. In this study, we aimed to determine for the first time whether the anti-TNF-a monoclonal antibody adalimumab may improve insulin sensitivity in non-diabetic patients with psoriasis. Methods: Prospective study on a series of consecutive non-diabetic patients with moderate to severe psoriasis seen at the Dermatology Division of Hospital Universitario Marques de Valdecilla (Northern Spain) who completed 6 months of therapy with adalimumab (80 mg at week 0 followed by 40 mg every other week, starting 1 week after the initial dose). Patients with chronic kidney disease, hypertension or body mass index = 35 kg/m(2) were excluded. Metabolic and clinical evaluation including assessment of insulin sensitivity using the Quantitative Insulin Sensitivity Check Index (QUICKI) was performed at the onset of the treatment (time 0) and at month 6. Results: Twenty-nine patients (52% women; 38.6 ± 10.7 years) with moderate to severe psoriasis [body surface area (BSA) 37.9 ± 16.3%], Psoriasis Area and Severity Index [(PASI) 18.9 ± 7.8] were assessed. Statistically significant improvement (P=0.008) of insulin sensitivity was observed after 6 months of adalimumab therapy (QUICKI at time 0: 0.35 ± 0.04 vs. 0.37 ± 0.04 at month 6). Significant improvement of erythrocyte sedimentation rate, ultrasensitive C-reactive protein, BSA, PASI, Nail Psoriasis Severity Index, physician global assessment and psoriatic arthritis screening and evaluation questionnaire was also observed at month 6 (P < 0.05 for each variable). Conclusion: Our results support a beneficial effect of the anti-TNF-a blockade on the mechanisms associated with accelerated atherogenesis in patients with psoriasis.

 Autoría: Pina T., Armesto S., Lopez-Mejias R., Genre F., Ubilla B., Gonzalez-Lopez M.A., Gonzalez-Vela M.C., Corrales A., Blanco R., Garcia-Unzueta M.T., Hernandez J.L., Llorca J., Gonzalez-Gay M.A.,

 Fuente: Journal of the European Academy of Dermatology and Venereology, 2015, 29(7),1325-130

 Editorial: Blackwell Publishing Ltd

 Año de publicación: 2015

 Nº de páginas: 6

 Tipo de publicación: Artículo de Revista

 DOI: 10.1111/jdv.12814

 ISSN: 0926-9959,1468-3083

 Url de la publicación: https://doi.org/10.1111/jdv.12814

Autoría

PINA, T

ARMESTO, S

LÓPEZ MEJÍAS, R

GENRE, FERNANDA

UBILLA GARCÍA, BEGOÑA

GONZÁLEZ LÓPEZ, MA

MARIA CARMEN GONZALEZ VELA

CORRALES, A

GARCÍA UNZUETA, MT

FRANCISCO JAVIER LLORCA DIAZ